PROCEPT BioRobotics (PRCT) Set to Announce Earnings on Wednesday

PROCEPT BioRobotics (NASDAQ:PRCT) will release its earnings data after the market closes on Wednesday, May 1st. Analysts expect PROCEPT BioRobotics to post earnings of ($0.55) per share for the quarter. PROCEPT BioRobotics has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative return on equity of 46.59% and a negative net margin of 77.75%. The business had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.79 million. During the same quarter last year, the firm posted ($0.56) EPS. The company’s revenue was up 83.3% compared to the same quarter last year. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PROCEPT BioRobotics Trading Up 5.0 %

Shares of NASDAQ PRCT opened at $53.75 on Wednesday. The stock’s 50 day moving average price is $49.09 and its two-hundred day moving average price is $42.16. PROCEPT BioRobotics has a 52-week low of $24.83 and a 52-week high of $54.50. The stock has a market capitalization of $2.74 billion, a P/E ratio of -23.90 and a beta of 1.01. The company has a quick ratio of 6.77, a current ratio of 7.63 and a debt-to-equity ratio of 0.18.

Analyst Ratings Changes

A number of analysts have recently weighed in on PRCT shares. Truist Financial increased their price target on PROCEPT BioRobotics from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Wells Fargo & Company increased their price target on PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $45.60.

Insider Activity

In other news, CFO Kevin Waters sold 904 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $50.00, for a total transaction of $45,200.00. Following the completion of the sale, the chief financial officer now owns 33,523 shares in the company, valued at approximately $1,676,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Reza Zadno sold 5,391 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $48.83, for a total value of $263,242.53. Following the completion of the sale, the chief executive officer now owns 241,319 shares in the company, valued at $11,783,606.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Waters sold 904 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $50.00, for a total value of $45,200.00. Following the completion of the sale, the chief financial officer now owns 33,523 shares of the company’s stock, valued at approximately $1,676,150. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,149 shares of company stock worth $4,653,720. Insiders own 19.60% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).